JP2012507994A5 - - Google Patents

Download PDF

Info

Publication number
JP2012507994A5
JP2012507994A5 JP2011535101A JP2011535101A JP2012507994A5 JP 2012507994 A5 JP2012507994 A5 JP 2012507994A5 JP 2011535101 A JP2011535101 A JP 2011535101A JP 2011535101 A JP2011535101 A JP 2011535101A JP 2012507994 A5 JP2012507994 A5 JP 2012507994A5
Authority
JP
Japan
Prior art keywords
polypeptide
hla
fusion polypeptide
antigen
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011535101A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012507994A (ja
Filing date
Publication date
Priority claimed from EP08168675A external-priority patent/EP2184070A1/en
Application filed filed Critical
Publication of JP2012507994A publication Critical patent/JP2012507994A/ja
Publication of JP2012507994A5 publication Critical patent/JP2012507994A5/ja
Pending legal-status Critical Current

Links

JP2011535101A 2008-11-07 2009-11-04 Hla−gタンパク質及びその薬学的使用 Pending JP2012507994A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08168675A EP2184070A1 (en) 2008-11-07 2008-11-07 HLA-G proteins and pharmaceutical uses thereof
EP08168675.0 2008-11-07
US11280408P 2008-11-10 2008-11-10
US61/112,804 2008-11-10
PCT/EP2009/064575 WO2010052228A1 (en) 2008-11-07 2009-11-04 Hla-g proteins and pharmaceutical uses thereof

Publications (2)

Publication Number Publication Date
JP2012507994A JP2012507994A (ja) 2012-04-05
JP2012507994A5 true JP2012507994A5 (enExample) 2012-12-06

Family

ID=40673439

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011535101A Pending JP2012507994A (ja) 2008-11-07 2009-11-04 Hla−gタンパク質及びその薬学的使用

Country Status (8)

Country Link
US (1) US20110268737A1 (enExample)
EP (2) EP2184070A1 (enExample)
JP (1) JP2012507994A (enExample)
CA (1) CA2742517A1 (enExample)
DK (1) DK2352509T3 (enExample)
ES (1) ES2423993T3 (enExample)
PT (1) PT2352509E (enExample)
WO (1) WO2010052228A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012530106A (ja) * 2009-06-18 2012-11-29 エイチエルエイ−ジー・テクノロジーズ HLA−Gα1多量体及びその薬学的使用
EP2445935B1 (en) * 2009-06-25 2015-07-01 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Multimeric polypeptides of hla-g including alpha1-alpha3 monomers and pharmaceutical uses thereof
BR112014017111A8 (pt) 2012-01-12 2018-05-15 Biogen Idec Inc métodos de redução de imunogenicidade contra o fator viii em indivíduos submetidos à terapia de fator viii
RU2015106812A (ru) 2012-08-02 2016-09-27 Ф.Хоффманн-Ля Рош Аг Способ получения мономерных и мультимерных молекул и их применение
JP2016500255A (ja) 2012-12-11 2016-01-12 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ ハイスループットなレセプター:リガンド同定の方法
US20170176435A1 (en) * 2014-01-21 2017-06-22 Albert Einstein College Of Medicine, Inc. Cellular platform for rapid and comprehensive t-cell immunomonitoring
JP6416480B2 (ja) * 2014-01-29 2018-10-31 国立大学法人北海道大学 関節リウマチまたはその関連疾患の予防または治療剤
US9765330B1 (en) 2015-01-09 2017-09-19 Nant Holdings Ip, Llc Compositions and methods for reduction of allograft recognition and rejection
JP7071288B2 (ja) 2016-05-18 2022-05-18 キュー バイオファーマ, インコーポレイテッド T細胞調節多量体ポリペプチド及びその使用方法
US11339201B2 (en) 2016-05-18 2022-05-24 Albert Einstein College Of Medicine Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
NZ748929A (en) * 2016-06-03 2025-11-28 Invectys Anti hla-g specific antibodies
KR20230110373A (ko) * 2016-06-14 2023-07-21 리전츠 오브 더 유니버스티 오브 미네소타 질환을 치료하기 위한 유전적으로 변형된 세포, 조직,및 장기
CN110520149A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 诱导对凝血因子的免疫耐受性的方法
MX2019007611A (es) 2016-12-22 2020-07-29 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos t y métodos para su uso.
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
CN118453840A (zh) 2017-03-15 2024-08-09 库尔生物制药有限公司 用于调节免疫应答的方法
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
JP2021080171A (ja) * 2018-03-13 2021-05-27 国立大学法人北海道大学 改変タンパク質、医薬品、炎症性疾患の予防又は治療剤及び改変タンパク質の製造方法
TW202208395A (zh) 2020-05-12 2022-03-01 美商信號生物製藥公司 多聚體t細胞調節多肽及其使用方法
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ, インコーポレイテッド 1型真性糖尿病(t1d)を治療するためのmhcクラスii t細胞調節多量体ポリペプチド及びその使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2717498B1 (fr) 1994-03-18 1996-05-03 Commissariat Energie Atomique Transcrits du gène de CMH de classe I HLA-G et leurs applications.
CA2321222A1 (fr) 1998-02-20 1999-08-26 Commissariat A L'energie Atomique Methode de selection de tumeurs exprimant hla-g, sensibles a un traitement anticancereux et ses applications
FR2794977B1 (fr) 1999-06-18 2003-10-31 Commissariat Energie Atomique Utilisation de compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau, et leur procede d'obtention
FR2810047B1 (fr) 2000-06-13 2004-04-02 Commissariat Energie Atomique Nouvelle isoforme d'hla-g et ses applications
WO2005063808A1 (en) * 2003-12-31 2005-07-14 Merck Patent Gmbh Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
MXPA06014689A (es) * 2004-06-18 2008-03-11 Regeneron Pharma Inhibidores del vegf para el tratamiento de efusion pleural maligna.
WO2007011044A1 (ja) 2005-07-15 2007-01-25 Kyushu University, National University Corporation ジスルフィド結合型hla-g二量体を含む医薬組成物及びジスルフィド結合型hla-g二量体の製造方法
WO2007091078A2 (en) 2006-02-10 2007-08-16 Axordia Limited Polypeptide conjugate comprising hla-g and uses thereof, stem cells transfected with hla-g
WO2007133811A2 (en) * 2006-05-15 2007-11-22 Viral Logic Systems Technology Corp. Cd47 related compositions and methods for treating immunological diseases and disorders

Similar Documents

Publication Publication Date Title
JP2012507994A5 (enExample)
JP2023076828A5 (enExample)
JP2019514361A5 (enExample)
JP2014519830A5 (enExample)
JP2025138715A5 (enExample)
JP2019521643A5 (enExample)
RU2015129640A (ru) Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1
JP2016527314A5 (enExample)
JP7536294B2 (ja) 抗体のFc領域改変体
JP2019507589A5 (enExample)
JP2017501728A5 (enExample)
JP2012514997A5 (enExample)
JP2013519721A5 (enExample)
JP2020517294A5 (enExample)
JP2016511277A5 (enExample)
JP2010227116A5 (enExample)
JP2015212284A5 (enExample)
JP2015518479A5 (enExample)
JP2019516665A5 (enExample)
TR201906652T4 (tr) Kademeli multimerize immünoglobülin fc bileşimleri oluşturmak için doğal insan protein fragmanları içeren füzyon proteinleri.
JP2020500015A5 (enExample)
JP2019504617A5 (enExample)
HRP20161542T1 (hr) MUTIRANA Fc ANTITIJELA SA UKLONJENOM EFEKTORSKOM FUNKCIJOM
JP2017527272A5 (enExample)
RU2015125639A (ru) Удаление раковых клеток с помощью циркулирующих вирус-специфических цитотоксических т-клеток с использованием направленных против раковых клеток многофункциональных белков, содержащих молекулу гкгс класса i